- $1.27m
- -$13.96m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.09 | ||
| Price to Tang. Book | 0.09 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -218.25% | ||
| Return on Equity | -150.65% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 0.56 | 0.07 | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Vaxxinity, Inc. is a biotechnology company. The Company is engaged in the development of rationally designed prophylactic and therapeutic vaccines to combat common chronic disorders and infectious diseases with large patient populations and unmet medical needs. Its synthetic peptide-based Active Immunotherapy Medicines Platform (AIM Platform, formerly called the Vaxxine Platform) has the potential to enable a new class of medicines. Its pipeline consists of five lead programs focused on chronic disease, particularly neurodegenerative disorders, in addition to other neurology and cardiovascular indications. Its pipeline includes UB-311, UB-312, VXX-301, VXX-401 and UB-313. It also has developed an infectious disease product candidate, UB-612, as a heterologous booster against COVID-19. Its UB-311, which targets the primary pathological process of Alzheimer’s disease (AD) and UB-312, which targets the pathological process of Parkinson’s disease (PD) and other so-called synucleinopathies.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 2nd, 2021
- Public Since
- November 11th, 2021
- No. of Shareholders
- 74
- No. of Employees
- 57
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Pink Sheets on Nasdaq- Shares in Issue
- 126,784,684
- Address
- 1717 Main Street, Suite 3388, DALLAS, 75201
- Web
- https://vaxxinity.com/
- Phone
- +1 2542445739
- Auditors
- FORVIS, LLP
Upcoming Events for VAXX
Q4 2024 Vaxxinity Inc Earnings Release
Similar to VAXX
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
What is the Vaxxinity share price?
As of Today at 23:56 UTC, shares in Vaxxinity are trading at $0.01. This share price information is delayed by 15 minutes.
How has the Vaxxinity share price performed this year?
Shares in Vaxxinity last closed at $0.01 and the price had moved by -97.61% over the past 365 days. In terms of relative price strength the Vaxxinity share price has underperformed the S&P500 Index by -97.74% over the past year.
What are the analyst and broker recommendations for Vaxxinity?
The overall consensus recommendation for Vaxxinity is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Vaxxinity dividend yield?
Vaxxinity does not currently pay a dividend.
Does Vaxxinity pay a dividend?
Vaxxinity does not currently pay a dividend.
When does Vaxxinity next pay dividends?
Vaxxinity does not currently pay a dividend.
How do I buy Vaxxinity shares?
To buy shares in Vaxxinity you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Vaxxinity?
As of the previous close price of $0.01, shares in Vaxxinity had a market capitalisation of $1.27m.
Where are Vaxxinity shares listed?
Here are the trading details for Vaxxinity:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: VAXX
What kind of share is Vaxxinity?
Based on an overall assessment of its quality, value and momentum Vaxxinity is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Vaxxinity share price forecast for 2025?
The analyst consensus target price for shares in Vaxxinity is $15.00. That is 149900% above the last closing price of $0.01.
Analysts covering Vaxxinity currently have a consensus Earnings Per Share (EPS) forecast of -$0.38 for the next financial year.
Find out moreWhat is the trend in the Vaxxinity share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vaxxinity. Over the past six months, its share price has outperformed the S&P500 Index by +440.11%.
As of the last closing price of $0.01, shares in Vaxxinity were trading -74.06% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Vaxxinity PE Ratio?
The Vaxxinity PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Vaxxinity?
We do not have data on Vaxxinity's directors